NCT05378633
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have 4-15 suspect intracranial lesions
Exclusions: Patients with previous radiotherapy to the brain; Patients with more than 15 suspect intracranial lesions; Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT05378633